|Day Low/High||18.35 / 18.99|
|52 Wk Low/High||13.63 / 25.06|
These names are at or near bearish territory based on technical patterns.
The Medical Technology Stock Letter's top pick rose 357% in 2019.
I see a lot of winners here because of hindsight.
Every year there are 'winners' and 'losers' from the biggest confab around oncology of the year.
These names are showing bullish and bearish technical patterns over the past week.
We see a notable shift away from traditional large-cap pharmaceutical stocks to more specialized niches.
It is premature to think that this market has hit a top until there is further evidence in the price action.
The New York-based firm reported net income of $5.25 per share, compared with a net loss of $1.71 per share, in the same period a year ago.
But what will be most important is whether support stays strong and the buyers show interest in the afternoon.
Why not buy something and try to make some money rather than waste time predicting how this will all come to an ugly end?
Biotech companies show more energy than the rest of the market Monday.
This morning I warned about an overbought group of market sectors/leaders. Thus far, (recent leaders) retail and financials are being taken out to the woodshed. Speculative biotech, like Intrexon , Portola Pharmaceuticals , SAGE Therapeutics ...
"Dougie, take what Mr. Market gives you." -- Grandma Koufax And I did, Grandma Koufax. A consecutive nine-day market drop was snapped as we regained most that was lost in that period. Today was a great day. (Boy, would I like to annualize the pe...
"You see, in this world there's two kinds of people, my friend: Those with loaded guns and those who dig. You dig." -- Blondie in "The Good, the Bad and the Ugly." I did very little today. Markets were higher from the get-go and seemed "stuck" nea...
The big issue is if the market can build on Friday's jobs good news.
The bears are trying it out on the Bank of England news today, but they may get squeezed.
Computer programming has found that buying bad-news dips is a consistent winner.
I started the day today by dissing the banks. Then, I unfriended Facebook (FB) by making it my Short Trade of the Week. Finally, I offered another critical post about auto stocks. Hey, at least I'm consistent! And at least I like Op...
I remain "all in short," positioned on Friday afternoon. My message for the day this morning? "Don't worship at the church of what's happening now." The key insight today was the flight to safety. More risk off might lie ahead. Thanks for the nic...
What a weekend at the First Annual RealMoneyPro Golf Tournament and Conference! Unprecedented fun!! Here is why I am "all in" short. I made some important portfolio changes today, selling six core long investments. I am at my largest net short po...
Given my risk-averse profile, I made the unusual move last week of buying a basket of biotech stocks. And yesterday, I noted that Biotech Could Be Close to a 'Double Bottom': "I recently created a basket of a dozen speculative and conservative biote...
Stocks are near the day's lows as I write this -- and an old traders' adage is to "buy what's green in a flow of red." That's not a strategy I plan to employ today. But for contrarians who are looking for some trades in a potential market turnaround...
The iShares Nasdaq Biotechnology ETF (IBB) has tumbled from nearly $400 a share early last summer to around $240 at last check, so I'm taking advantage of today's market schmeissing to purchase a small position in a biotech (biowreck?). I'm buying a...
The market is rolling over following initial confusion over the Supreme Court's Obamacare decision.
There's been an important change in the last two days, emphasized by a jump in volume to the downside.